[Impact of an anti-hepatitis B virus (HBV) immunization program in patients undergoing dialysis in Havana, Cuba].
The follow-up of HBV markers in selected high infection risk populations, in patients from the hemodialysis and peritoneal dialysis services was used to assess the effectiveness of a special vaccination program. Viral infection markers were studied in prevalence cross sections of the whole population of patients, and also by recording the reports of clinical cases of hepatitis B occurred during that period in those groups of patients. The prevention program consisted of the vaccination of all patients negative to the viral markers and the indication of vaccination for the new cases during the period of the kidney disease, just before the start of the treatment at the hemodialysis unit; besides all the persons susceptible to infection that had already been included in the program, regardless of the stage of the disease. The results show the benefit of the vaccination in these patients, but it is more effective in the period before the treatment with dialysis where there is a lower possibility of being exposed to the virus and the immune system is still competent. Once the program was established, after a follow up o 6 years, there have been no reports of new cases of hepatitis B and the incidence of the disease has been declining.
González-Griego
M
M
División de Farmacéuticos, Centro de Ingeniería Genética y Biotecnología (CIGB), Aptdo, Postal 6162, C. de La Habana CP10600, Cuba. martagonzalez@cigb.edu.cu
Pentón
E
E
Delgado
G
G
Pérez-Oliva
J
J
Ramos
V
V
Izquierdo
M
M
García
G
G
Levy
N
N
Cinza
Z
Z
Valdivia
I
I
Trujillo
J
J
Delahanty
A
A
D000328:Adult; D015415:Biomarkers / Q000032:analysis; D003462:Cuba / Q000453:epidemiology; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006526:Hepatitis C / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D017589:Immunization Programs / Q000458:organization & administration*; D015397:Program Evaluation; D006435:Renal Dialysis
D015415:Biomarkers; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens